Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2005

View Archived Issues

New therapeutics for cancer disclosed in recent patents

Antisense oligomers effective against intraperitoneal infection in mice

Sepracor enjoys progress on multiple fronts

Cerexa begins operations

Nobex and Biocon to codevelop oral BNP for cardiovascular disease

Biovitrum acquires Arexis

Fibrex Medical receives funding for FX-06 in sepsis

New investment supports 7TM's metabolic disorders programs

Exelixis plans phase II studies for most advanced compounds

GSK-3: an important target for opioid tolerance

TRPA1: a novel target for analgesics

Preclinical studies reveal novel treatment options for bone cancer pain

Adderall XR marketing authorization reinstated in Canada

Court rules in favor of Ivax in summary judgment ruling for gabapentin

EndoTAG-1 begins phase II study in advanced pancreatic cancer

mGluR5 blockade facilitates the reversal of nerve injury induced pain

GW-406381: effective for neuropathic and centrally mediated pain

European Commission clears Johnson & Johnson's acquisition of Guidant

APD-356 shows no apparent effect on heart valves or pulmonary artery pressure

DB-289 begins phase III study for trypanosomiasis

Extended-use study for Xerecept

Guidant cleared to expand SPIRIT III trial of Xience V stent

Isis grants iCo license for ISIS-13650 for eye diseases

BMS-505130 robustly increases serotonin levels in rats

Recent Vertex and GSK patents disclose novel analgesic agents

New anti-HIV agents described in patents

Novel alpha3 selective GABA-A receptor agonist described